Skip to main content

Ongentys Disease Interactions

There are 6 disease interactions with Ongentys (opicapone).

Major

Opicapone (applies to Ongentys) pheochromocytoma

Major Potential Hazard, Moderate plausibility. Applicable conditions: Adrenal Tumor

The use of opicapone is contraindicated in patients with pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.

References

  1. (2020) "Product Information. Ongentys (opicapone)." Neurocrine Biosciences, Inc.
Major

Opicapone (applies to Ongentys) psychosis

Major Potential Hazard, Moderate plausibility.

Opicapone may cause impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating, and compulsive eating. Patients with a major psychotic disorder should ordinarily not be treated with this drug because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.

References

  1. (2020) "Product Information. Ongentys (opicapone)." Neurocrine Biosciences, Inc.
Moderate

Opicapone (applies to Ongentys) end stage renal disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The pharmacokinetics of opicapone have not been studied in patients with end stage renal disease. Caution is advised.

References

  1. (2020) "Product Information. Ongentys (opicapone)." Neurocrine Biosciences, Inc.
Moderate

Opicapone (applies to Ongentys) hypotension

Moderate Potential Hazard, Moderate plausibility.

Opicapone may cause orthostatic blood pressure changes including fainting and dizziness and patients should be advised to avoid standing rapidly after sitting or lying down. Caution is advised in patients with hypotension.

References

  1. (2020) "Product Information. Ongentys (opicapone)." Neurocrine Biosciences, Inc.
Moderate

Opicapone (applies to Ongentys) liver impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The mean overall plasma exposure (AUC) of opicapone increased by 84% in patients with moderate (Child-Pugh Class B) liver dysfunction. A dosage adjustment is required on these patients. The pharmacokinetics of this drug have not been studied in patients with severe liver dysfunction (Child-Pugh: C). Caution is advised.

References

  1. (2020) "Product Information. Ongentys (opicapone)." Neurocrine Biosciences, Inc.
Moderate

Poicapone (applies to Ongentys) lactose intolerance

Moderate Potential Hazard, Moderate plausibility.

Opicapone formulations contain lactose. Caution is advised if used in patients with lactose intolerance.

References

  1. (2020) "Product Information. Ongentys (opicapone)." Neurocrine Biosciences, Inc.

Ongentys drug interactions

There are 276 drug interactions with Ongentys (opicapone).

Ongentys alcohol/food interactions

There are 2 alcohol/food interactions with Ongentys (opicapone).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer